MannKind Corp
NASDAQ:MNKD

Watchlist Manager
MannKind Corp Logo
MannKind Corp
NASDAQ:MNKD
Watchlist
Price: 6.84 USD -0.87% Market Closed
Market Cap: 1.9B USD
Have any thoughts about
MannKind Corp?
Write Note

MannKind Corp
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

MannKind Corp
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
MannKind Corp
NASDAQ:MNKD
Research & Development
-$44m
CAGR 3-Years
-24%
CAGR 5-Years
-49%
CAGR 10-Years
9%
Abbvie Inc
NYSE:ABBV
Research & Development
-$7.9B
CAGR 3-Years
-4%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.5B
CAGR 3-Years
-4%
CAGR 5-Years
10%
CAGR 10-Years
-9%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$5.8B
CAGR 3-Years
-7%
CAGR 5-Years
-8%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.5B
CAGR 3-Years
-7%
CAGR 5-Years
-15%
CAGR 10-Years
-14%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$4.9B
CAGR 3-Years
-20%
CAGR 5-Years
-14%
CAGR 10-Years
-15%
No Stocks Found

MannKind Corp
Glance View

Market Cap
1.9B USD
Industry
Biotechnology

MannKind Corp. operates as a biopharmaceutical company. The company is headquartered in Danbury, Connecticut and currently employs 348 full-time employees. The company went IPO on 2004-07-28. The firm is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.

MNKD Intrinsic Value
5.81 USD
Overvaluation 15%
Intrinsic Value
Price

See Also

What is MannKind Corp's Research & Development?
Research & Development
-44m USD

Based on the financial report for Sep 30, 2024, MannKind Corp's Research & Development amounts to -44m USD.

What is MannKind Corp's Research & Development growth rate?
Research & Development CAGR 10Y
9%

Over the last year, the Research & Development growth was -50%. The average annual Research & Development growth rates for MannKind Corp have been -24% over the past three years , -49% over the past five years , and 9% over the past ten years .

Back to Top